Need for an increasing awareness for heparin-induced skin lesions

Expert Review of Dermatology

Volumn 5, Issue 1, 2010, Pages 1-3

  Schindewolf, Marc ^a   Ludwig, Ralf J ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; FONDAPARINUX; HEPARIN; NADROPARIN;

ANTICOAGULATION; BLEEDING; CROSS REACTION; DELAYED HYPERSENSITIVITY; EARLY DIAGNOSIS; EDITORIAL; GENDER; HAIR LOSS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; OBESITY; OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SKIN DEFECT; TREATMENT DURATION;

EID: 77951623883     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/edm.09.66     Document Type: Editorial

References (29)

1. Crafoord C. Preliminary report on postoperative treatment with heparin as a preventive of thrombosis. Acta Chir. Scand. 79, 407-426 (1937).
2. Alban S. From heparins to factor Xa inhibitors and beyond. Eur. J. Clin. Invest. 35 (Suppl. I), 12-20 (2005).
3. Warkentin TE. Heparin-induced thrombocytopenia. Hematol. Oncol. Clin. North Am. 21(4) 589-607 (2007).
4. Bick RL, Frenkel EP. Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy. Clin. Appl. Thromb. Hemost. 5, S7-S15 (1999).
5. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 61, 1432-1440 (2006).
6. Ludwig RJ, Schindewolf M, Utikal J, Lindhoff-Last E, Boehncke WH. Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb. Haemost. 96, 611-617 (2006).
7. Utikal J, Peitsch WK, Booken D et al. Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thromb. Haemost. 94, 895-896 (2005).
8. Hirsch K, Ludwig RJ, Lindhoff-Last E, Kaufmann R, Boehncke WH. Intolerance of fondaparinux in a patient allergic to heparins. Contact Dermatitis 50, 383-384 (2004).
9. Ludwig RJ, Beier C, Lindhoff-Last E, Kaufmann R, Boehncke WH. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans. Contact Dermatitis 49, 158-159 (2003).
10. Jappe U, Juschka U, Kuner N, Hausen BM, Krohn K. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases. Contact Dermatitis 51, 67-72 (2004).
11. Schindewolf M, Schwaner S, Wolter M et al. Incidence and causes of heparin-induced skin lesions. CMAJ 181, 477-481 (2009).
12. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 127, 1857-1861 (2005).
13. Gaigl Z, Pfeuffer P, Raith P, Brocker EB, Trautmann A. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br. J. Haematol. 128(3), 389-392 (2005).
14. Schindewolf M, Ludwig RJ, Wolter M et al. Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin. J. Eur. Acad. Dermatol. Venereol. 22, 378-380 (2008).
15. Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological profle: an update. Blood Coagul. Fibrinolysis 17(8), 605-613 (2006).
16. Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thromb. Haemost. 94, 1265-1269 (2005).
17. Ludwig RJ, Schindewolf M, Lindhoff-Last E, Boehncke WH. The infuence of heparin's molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al. Br. J. Dermatol. (2007) 157, 514-517.
18. Br. J. Dermatol. 154, 849-851 (2008).
19. Grims RH, Weger W, Reiter H, Arbab E, Kranke B, Aberer W. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Br. J. Dermatol. 157, 514-517 (2007).
20. Ludwig RJ, Schon MP, Boehncke WH. P-selectin: a common therapeutic target for cardiovascular disorders, infammation and tumor metastasis. Expert Opin. Ther. Targets 11, 1103-1117 (2007).
21. Alban S, Ludwig RJ, Bendas G et al. PS3, a semisynthetic b-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L-and P-selectin functions. J. Invest. Dermatol. 129, 1192-1202 (2009).
22. Ludwig RJ, Alban S, Boehncke WH. Structural requirements of heparin and related molecules to exert a multitude of anti-infammatory activities. Mini Rev. Med. Chem. 6, 1009-1023 (2006).
23. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl Acad. Sci. USA 98, 3352-3357 (2001).
24. Ludwig RJ, Boehme B, Podda M et al Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 64, 2743-2750 (2004).
25. Lebeau B, Chastang C, Brechot JM et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. 'Petites Cellules' Group. Cancer 74, 38-45 (1994). (Pubitemid 24187607)
26. Klerk CPW, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 23, 2130-2135 (2005).
27. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 22(10), 1944-1948 (2004).
28. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin. Cancer Res. 11, 7003-7011 (2005).
29. Ludwig RJ, Alban S, Bislian R et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on blood-borne metastasis in vivo. Thromb. Haemost. 95, 535-540 (2006).